Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Parkinson's Disease
Trial Information
Evaluate the Effects of Coenzyme Q-10 in Early Parkinson’s Disease
This is a multi-center, randomized, double-blind, placebo controlled, NIH-funded study to Evaluate the Effects of Coenzyme Q-10 in Early Parkinson’s disease. It is being organized by the Parkinson’s Study Group.
The duration of the study is a maxiumum of 16 months.
The study will be conducted at the Einstein Institute for Clinical and Translational Research.
Patient Inclusion Criteria:
- Presence of the 3 cardinal features of Parkinson’s disease (rest tremor, bradykinesia and rigidity). These signs must be asymmetric.
- Age 30 or older
- Subject discontinued taking Coenzyme Q-10 during past 60 days (if 300 mg or less), past 90 days (if 301-600 mg) or past 120 days (if greater than 600 mg)
Patient Exclusion Criteria:
- Use of any Parkinson’s disease medication within the past 60 days and the duration of any symptomatic treatment cannot exceed 90 days
- Need for symptomatic treatment with dopaminergic therapy (Sinemet or dopamine agonists or amantadine) -Use of antioxidants
- Use of neuroleptics
Dr. Cathy Chuang, Assistant Professor
Einstein-Montefiore Institute for Clinical & Translational Research
1300 Morris Park Avenue
Bronx, NY 10461
Phone: 718-918-7895 / 917-833-3857 (cell)
EMail: cathychuang@usa.net
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
